Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors

• Published in: Journal of neuro-oncology 2024-06, Vol.168 (2), p.215-224
• Main Authors: Ronsley, Rebecca, Karvonen, Kristine A., Cole, Bonnie, Paulson, Vera, Stevens, Jeff, Crotty, Erin E., Hauptman, Jason, Lee, Amy, Stasi, Shannon M., Lockwood, Christina M., Leary, Sarah E. S.
• Format: Article
• Language: English
• Subjects: Astrocytes; Astrocytoma; Biopsy; Brain cancer; Brain tumors; Central nervous system; Central nervous system diseases; Cerebrospinal fluid; Deoxyribonucleic acid; DNA; DNA sequencing; Medicine; Medicine & Public Health; Medulloblastoma; Neurology; Neurosurgery; Next-generation sequencing; Oncology; Patients; Pediatrics; Tumors
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-024-04645-y

Purpose Clinical sequencing of tumor DNA is necessary to render an integrated diagnosis and select therapy for children with primary central nervous system (CNS) tumors, but neurosurgical biopsy is not without risk. In this study, we describe cell-free DNA (cfDNA) in blood and cerebrospinal fluid (CSF) as sources for “liquid biopsy” in pediatric brain tumors. Methods CSF samples were collected by lumbar puncture, ventriculostomy, or surgery from pediatric patients with CNS tumors. Following extraction, CSF-derived cfDNA was sequenced using UW-OncoPlex™, a clinically validated next-generation sequencing platform. CSF-derived cfDNA results and paired plasma and tumor samples concordance was also evaluated. Results Seventeen CSF samples were obtained from 15 pediatric patients with primary CNS tumors. Tumor types included medulloblastoma ( n  = 7), atypical teratoid/rhabdoid tumor ( n  = 2), diffuse midline glioma with H3 K27 alteration ( n  = 4), pilocytic astrocytoma ( n  = 1), and pleomorphic xanthoastrocytoma ( n  = 1). CSF-derived cfDNA was detected in 9/17 (53%) of samples, and sufficient for sequencing in 8/10 (80%) of extracted samples. All somatic mutations and copy-number variants were also detected in matched tumor tissue, and tumor-derived cfDNA was absent in plasma samples and controls. Tumor-derived cfDNA alterations were detected in the absence of cytological evidence of malignant cells in as little as 200 µl of CSF. Several clinically relevant alterations, including a KIAA1549::BRAF fusion were detected. Conclusions Clinically relevant genomic alterations are detectable using CSF-derived cfDNA across a range of pediatric brain tumors. Next-generation sequencing platforms are capable of producing a high yield of DNA alterations with 100% concordance rate with tissue analysis.